News & articles
RetatrutideTriple incretin agonist activating GLP-1, GIP, and glucagon receptors. The most comprehensive metabolic receptor coverage in a single peptide.
Lilly Reports Phase 3 TRIUMPH Data for Retatrutide, a GLP-1/GIP/Glucagon Triple AgonistEli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.
- ENDO 2026: GLP-1 and Multi-Agonist Peptides Dominate Chicago Readouts
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.
GLP-3RT 30mgProduct Type:Triple Agonist Peptide / Advanced Metabolic EnhancerCOA Specification: 30mg per vialShort Introduction:GLP-3RT 30mg is a potent triple agonist peptide (targeting GLP-1, GIP, and glucagon receptors) designed for maximum weight loss and metabolic improvement. It effectively suppresses app